Cheetah Medical Closes $20 million Series B Financing

Cheetah Medical, a worldwide leader in noninvasive hemodynamic and cardiac output
monitoring technology, announced today the closing of a $20 million financing round. The financing was led by Ascension Health Ventures (AHV) and also included Robert Bosch Venture Capital (RBVC), MVM Life Science Partners (MVM) and existing investors.

“We are very excited by the level of support provided by Cheetah’s distinguished new investors, who share our vision for the extraordinary potential of the NICOM platform,” commented Yoav Avidor, M.D., Chief Executive Officer of Cheetah Medical. “By providing accurate, noninvasive, continuous hemodynamic information, NICOM can improve patient outcomes by helping clinicians optimize fluid and vasoactive drug management in areas such as critical care, anesthesia, emergency medicine and heart failure. Patients worldwide are already benefiting from the NICOM platform, and the support of our investors enables continued expansion to new clinicians, applications and global markets.”

As a result of the financing, Dr. Walter Lin, an Investment Manager with AHV, Gadi Toren, Venture Capital Investment Partner with RBVC, and Dr. Stephen Reeders, a Managing Partner with MVM, have joined the company’s board.

“Because of its accuracy and non-invasiveness, Cheetah’s NICOM platform has the potential to significantly expand the hemodynamic monitoring market,” said Dr. Walter Lin of AHV. “We are excited to partner with a company whose validated technology can both improve outcomes and reduce the cost of care in what is generally a high acuity patient population.”

Decisions regarding appropriate fluid administration and titration of drugs that support the cardiovascular system have a profound impact on patient survival, complications and cost of care. These concepts, also known as fluid optimization and goal directed therapy, are increasingly becoming standard of care. This is especially true in those who are critically ill, such as patients with sepsis, heart failure, kidney failure, and trauma, or those undergoing major surgical procedures.

NICOM provides a simple to use platform that enables physicians and nurses to quickly obtain accurate advanced hemodynamic parameters at the bedside, thereby aiding in differential diagnosis and selection and titration of the appropriate therapy to individualize patient care. Legacy approaches that rely on invasive, costly catheters have more limited use due to concerns about cost, maintenance requirements, invasiveness and potential complications. NICOM provides accurate hemodynamic information through a safe, cost effective, user-friendly platform that can be utilized by physicians, nurses and other clinicians.

Cheetah Medical, Inc.

Cheetah Medical, Inc.
Non-invasive haemodynamic monitoring

Downloads

DownloadFull Press Release

Latest News

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera

MVM Life Science Partners LLP closes MVM IV

MVM Life Science Partners LLP announces the closing of a $233 million healthcare fund, MVM IV.